Updates are available Correction dated 2018-09-21
Click to view Correction: https://doi.org/10.1186/s13014-018-1134-7
-
Authors
Wiedenmann, Nicole https://orcid.org/0000-0002-5976-8829
Bunea, Hatice
Rischke, Hans C.
Bunea, Andrei
Majerus, Liette
Bielak, Lars
Protopopov, Alexey
Ludwig, Ute
Büchert, Martin
Stoykow, Christian
Nicolay, Nils H.
Weber, Wolfgang A.
Mix, Michael
Meyer, Philipp T.
Hennig, Jürgen
Bock, Michael
Grosu, Anca L.
-
Funding
Funding for this research was provided by:
German Cancer Consortium
- License Information
-
More Information
Article History
Received: 6 June 2018
Accepted: 17 August 2018
First Online: 29 August 2018
Change Date: 21 September 2018
Change Type: Correction
Change Details: Following the publication of this article [1], the authors noticed that figures 2, 3, 4 and 5 were in the incorrect order and thus had incorrect captions.
Ethics approval and consent to participate
: The study was approved by the Federal Office for Radiation Protection, the German Federal Institute for Drugs and Medical Devices, and the local ethics committee. Production and use of PET radiopharmaceuticalF-fluoromisonidazole (F-MISO) was approved and registered at the appropriate authority. All patients gave written informed consent prior to undergoing imaging (MRI and PET/CT) and radiotherapy.
: Written informed consent for data analysis and publication was obtained from all patients.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
